<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6516">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03022097</url>
  </required_header>
  <id_info>
    <org_study_id>D6570C00002</org_study_id>
    <secondary_id>M-AS464-30</secondary_id>
    <nct_id>NCT03022097</nct_id>
  </id_info>
  <brief_title>Study to Patients With Stable COPD to Assess the Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate (DUAKLIR)</brief_title>
  <acronym>AVANT</acronym>
  <official_title>A 24-week Treatment, Randomised, Parallel-group, Double Blinded, Double-Dummy, Multicenter Study to Assess the Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Compared With Individual Components and Placebo and Aclidinium Bromide Compared With Placebo When Administered to Patients With Stable Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multiple dose, randomised, parallel, double blind, double dummy, multicentre and
      multinational Phase III study to determine the efficacy and safety of Aclidinium
      bromide/Formoterol fumarate compared with individual components and placebo and Aclidinium
      bromide compared with Placebo when administered to patients with stable Chronic Obstructive
      Pulmonary Disease (COPD).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 24, 2017</start_date>
  <completion_date type="Anticipated">July 13, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 13, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in 1-hour morning post-dose dose Forced expiratory volume in 1 second (FEV1)</measure>
    <time_frame>Week 24</time_frame>
    <description>Change from baseline in 1-hour morning post-dose dose FEV1 of Aclidinium bromide 400 μg/Formoterol fumarate 12 μg compared to Aclidinium bromide at Week 24.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in morning pre-dose (trough) FEV1</measure>
    <time_frame>Week 24</time_frame>
    <description>Change from baseline in morning pre-dose (trough) FEV1 of Aclidinium bromide 400 μg/Formoterol fumarate 12 μg compared to Formoterol fumarate at Week 24.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in trough FEV1</measure>
    <time_frame>Week 24</time_frame>
    <description>Change from baseline in trough FEV1 of Aclidinium bromide 400 μg compared to placebo at Week 24.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in peak FEV1</measure>
    <time_frame>Week 24</time_frame>
    <description>Change from baseline in peak FEV1 of Aclidinium bromide 400 μg compared to placebo at week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvements Transition Dyspnoea Index (TDI) focal score</measure>
    <time_frame>Week 24</time_frame>
    <description>Improvements TDI focal score of Aclidinium bromide 400 μg/Formoterol fumarate 12 μg and Aclidinium bromide 400μg compared to placebo at week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in St Georges Respiratory Questionnaire (SGRQ) total score</measure>
    <time_frame>Week 24</time_frame>
    <description>Change from baseline in SGRQ total score of Aclidinium bromide 400 μg/Formoterol fumarate 12 μg and Aclidinium bromide 400μg compared to placebo at week 24</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1060</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Experimental 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aclidinium bromide 400μg/Formoterol fumarate 12 μg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aclidinium bromide 400 μg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Formoterol fumarate 12 μg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)</intervention_name>
    <description>Inhaled Aclidinium bromide/formoterol Fixed-Dose Combination (FDC), twice per day via Genuair</description>
    <arm_group_label>Experimental 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aclidinium bromide</intervention_name>
    <description>Inhaled Aclidinium bromide 400 μg, twice per day via Genuair</description>
    <arm_group_label>Experimental 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol Fumarate</intervention_name>
    <description>Inhaled Formoterol Fumarate 12 μg, twice per day via Turbuhaler</description>
    <arm_group_label>Comparator</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inhaled dose-matched placebo, twice per day via Genuair or via Turbuhaler</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Adult male or non-pregnant, non-lactating female patients aged ≥40

          -  2. Patients with a diagnosis of COPD (GOLD guidelines, 2015) for a period of at least
             6 months prior to Visit 1 (screening)

          -  3. Patients with moderate to severe stable COPD (Stage II or Stage III, according to
             GOLD Guidelines 2015) at Visit 1: post-bronchodilator FEV1 ≥30% and &lt; 80% and
             post-bronchodilator FEV1/Forced vital capacity (FVC) &lt; 70%

          -  4. Current or former smokers with a smoking history of ≥ 10 pack-years

          -  5. Patients able to perform repeatable pulmonary function testing for FEV1 according
             to the American Thoracic Society (ATS)/European Respiratory Society (ERS) 2005
             criteria at Visit 1(screening )

          -  6. 6. Patients who understand the study procedures and are willing to participate in
             the study as indicated by signing the informed consent

        Exclusion Criteria:

          -  1. Involvement in the planning and/or conduct of the study (applies to AstraZeneca
             staff and/or site staff) or patients employed by or relatives of the employees of the
             site or sponsor.

          -  2. Previous enrolment or randomisation in the present study

          -  3. History or current diagnosis of asthma

          -  4. Any respiratory tract infection (including the upper respiratory tract) or COPD
             exacerbation (including the mild COPD exacerbation) within 6 weeks prior to screening
             or during the run-in period

          -  5. Patients hospitalized for COPD exacerbation (an emergency room visit for longer
             than 24 hours will be considered a hospitalization) within 3 months prior to
             screening and during the run-in period

          -  6. Clinically significant respiratory conditions other than COPD

          -  7. Patients who in the Investigator's opinion may need to start a pulmonary
             rehabilitation program during the study and/or patients who started/finished it
             within 3 months prior to screening

          -  8. Use of long-term oxygen therapy (≥15 hours/day)

          -  9. Patient who does not maintain regular day/night, waking/sleeping cycles including
             night shift workers

          -  10. Clinically significant cardiovascular conditions

          -  11. Patients with Type I or uncontrolled Type II diabetes, uncontrolled hypo-or
             hyperthyroidism, hypokalaemia, or hyperadrenergic state, uncontrolled or untreated
             hypertension

          -  12. Patients with QT corrected interval (QTc) using Fridericia formula (QTcF)
             (QTc=QT/ Duration in milliseconds between two R peaks of two consecutive QRS
             complexes (RR1/3) &gt;470 msec as indicated in the centralised reading report assessed
             at Screening (Visit 1)

          -  13. Patients with clinically significant abnormalities in the clinical laboratory
             tests, ECG parameters (other than QTcF) or in the physical examination at Visit 1
             (screening)

          -  14. Patients with abnormal liver function tests defined as Aspartate aminotransferase
             (AST), Alanine aminotransferase (ALT), or total bilirubin ≥ 2.5 times upper limit of
             normal ranges at screening

          -  15. Patient with known non-controlled history of infection with human
             immunodeficiency virus and/or active hepatitis

          -  16. Patient with a history of hypersensitivity reaction to inhaled anticholinergic
             drugs, sympathomimetic amines, inhaled medication or any component thereof

          -  17. Patient with known narrow-angle glaucoma, symptomatic bladder neck obstruction,
             acute urinary retention, or patients with symptomatic non-stable prostatic
             hypertrophy

          -  18. History of malignancy of any organ system (including lung cancer), treated or
             untreated, within the past 5 years other than basal or squamous cell skin cancer

          -  19. Any other serious or uncontrolled physical or mental dysfunction

          -  20. Patients with a history (within 2 years prior to Visit 1 (screening) of drug
             and/or alcohol abuse that may prevent study compliance based on the Investigator
             judgment

          -  21. Patients unlikely to be cooperative or cannot comply with the study procedures

          -  22. Patients treated with any investigational drug within 30 days (or 6 half-lives,
             whichever is longer) prior to screening

          -  23. Patients who intended to use any concomitant medication not permitted by this
             protocol or who had not undergone the required washout period for a particular
             prohibited medication

          -  24. Patients unable to give consent, or patients of consenting age but under
             guardianship, or vulnerable patients

          -  25. Any other conditions that, in the Investigator's opinion, might have indicated
             the patient to be unsuitable for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baotou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fuzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Haikou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Haikou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hohhot</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nanchang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nanchang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shengyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shijiazhuang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Xian</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yanji</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zhanjiang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zhuhai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ahmedabad</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alappuzha</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ernakulam District</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guntur</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jaipur</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kozhikode</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mysore</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagpur</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vijayawada</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Caloocan City</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iloilo City</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Keelung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taichung City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ho Chi Minh City</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ho Chi Minh</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
    <country>India</country>
    <country>Philippines</country>
    <country>Taiwan</country>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 3, 2017</lastchanged_date>
  <firstreceived_date>January 13, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
